Oncological safety of extraoral photobiomodulation in patients with oral and oropharyngeal squamous cell carcinoma - PBM-OM Photobiomodulation for oral mucositis

Alan Roger Roger dos Santos Silva0 个研究点开始时间: 2020年1月20日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients diagnosed with oral cavity (C02, C03, C04, C05, C06) or oropharyngeal (C10) squamous cell carcinoma;
•Patients with III/IV stage tumors according to the International Union Against Cancer (TNM) system;
•Patients that underwent dental treatment prior to the oncological treatment;
•Patients who will be submitted to RT (radiotherapy) based on Elekta Synergy 6-mV linear accelerators (Elekta AB, Stockholm, Sweden) with planning on conformational three-dimensional basis or IMRT as a form of oncological treatment alone or in combination with surgery or chemotherapy;
•Should receive at least 60 Gy in the primary radiation field;
•Demographic and clinicopathological information, including gender, age, habits (smoking and alcoholism), medical and family history, location of the primary tumor, clinical staging (TNM), and type of treatment are available in the medical records;

•Patients with squamous cell carcinoma located in other topographies of the head and neck region;
•Patients who did not receive dental treatment prior to radiotherapy (RT);
•Patients who will be submitted to RT regimens different from those included in the inclusion criteria;
•Patients whose demographic and clinicopathological information is not fully available in the medical records;

发起方

Alan Roger Roger dos Santos Silva